Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bishop

Showing results (851-860 of 1,042) with videos related to

Pageof 105
Sort By:
Journal of Cancer|May 23, 2017
Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell TransplantationYee Chung Cheng, Yushu Shi, Mei-Jie Zhang, et al.
Blood|June 5, 2008
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse populationSumithira Vasu, Susan F Leitman, John F Tisdale, et al.
Cytotherapy|December 9, 2003
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind studyS S Joshi, M R Bishop, J C Lynch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant researchSteven Z Pavletic, Issa F Khouri, Michael Haagenson, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
Blood Advances|November 10, 2022
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapyKitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, et al.
Cancer Immunology Research|May 11, 2026
Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment EfficacyErting Tang, Yifei Hu, Guoshuai Cao, et al.
Blood Advances|June 24, 2026
Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium AnalysisKitsada Wudhikarn, Maria Bromberg, Jamie Brower, et al.
Schizophrenia Bulletin|March 13, 2014
Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disordersLeah H Rubin, C Sue Carter, Jeffrey R Bishop, et al.
British Journal of Haematology|September 9, 2004
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantationMichael R Bishop, Seth M Steinberg, Ronald E Gress, et al.
Pageof 105

Showing results (851-860 of 1,042) with videos related to

Sort By:
Pageof 105
Journal of Cancer|May 23, 2017
Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell TransplantationYee Chung Cheng, Yushu Shi, Mei-Jie Zhang, et al.
Blood|June 5, 2008
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse populationSumithira Vasu, Susan F Leitman, John F Tisdale, et al.
Cytotherapy|December 9, 2003
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind studyS S Joshi, M R Bishop, J C Lynch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant researchSteven Z Pavletic, Issa F Khouri, Michael Haagenson, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
Blood Advances|November 10, 2022
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapyKitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, et al.
Cancer Immunology Research|May 11, 2026
Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment EfficacyErting Tang, Yifei Hu, Guoshuai Cao, et al.
Blood Advances|June 24, 2026
Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium AnalysisKitsada Wudhikarn, Maria Bromberg, Jamie Brower, et al.
Schizophrenia Bulletin|March 13, 2014
Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disordersLeah H Rubin, C Sue Carter, Jeffrey R Bishop, et al.
British Journal of Haematology|September 9, 2004
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantationMichael R Bishop, Seth M Steinberg, Ronald E Gress, et al.
Pageof 105